“So as we look ahead to ATTAIN-2, we expect similarly encouraging results.”

In context

“t, that will continue. Operator: The next question will be from Terence Flynn from Morgan Stanley. Terence C. Flynn: Congrats on all the progress. Just wondering on orforglipron in light of the ATTAIN-1 data, if you can just frame expectations for us down for the upcoming ATTAIN-2 Phase III data. And then any early insights into the potential CMMI obesity, Medicare/Medicaid pilot that I think we saw some press reports about? Michael Czapar: For that we'll go to Ken to answer the question on expectations for ATTAIN-2. Kenneth L. Custer: Thanks, Terence, for the question on ATTAIN-2. We're very pleased with what we disclosed this morning in ATTAIN-1, which is our first Phase III study in obesity without diabetes. And of course, we had a great result with ACHIEVE-1 in patients with diabetes. So as we look ahead to ATTAIN-2, we expect similarly encouraging results. The exciting thing about ATTAIN-2 is that will be our third Phase III study, and it sets us up to submit to in obesity by the end of this year. So really no change in expectations here. The team is full speed ahead preparing for submission by year-end and a potential approval next year. Operator: Q - Courtney Breen: Courtney Breen: Just coming back to another question on orfo. As we looked at kind of comparing the data between ATTAIN-1 and ACHIEVE-1, we do see that kind of nausea, vomiting, constipation all appear a bit higher in this ACHIEVE-1 study. Can you talk a little bit about the differences in those data points that we're seeing between those 2 studies and what that might mean for adherence in the real world? Michael Czapar: Courtney, thanks for the question on comparing ACHIEVE v”